SCSheue-Yann Cheng

Sheue-Yann Cheng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sheue-Yann Cheng has a total of 61 co-authors. Here are the top co-authors by number of shared publications:

  • Mark C. Willingham

    Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland,1 Department of Pathology, Wake Forest University, Winston-Salem, North Carolina,2 Department of Cell Biology, Baylor College of Medicine, Houston, Texas3

    6 shared publications
  • Hao Ying

    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4264

    4 shared publications
  • Masahiro Kaneshige

    Laboratory of Molecular Biology, National Cancer Institute, †Genetic Disease Research Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892; ‡Frederick Cancer Research and Development Facility, Frederick, MD 21702-1201; §Laboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, CA 92037-1099; and ¶Department of Pathology, Wake Forest University School of Medicine, Winston-Salem, NC 27157

    4 shared publications
  • Hideyo Suzuki

    Laboratory of Molecular Biology, National Cancer Institute, Bethesda, MD 20892-4264, USA

    3 shared publications
  • Li Zhao

    Laboratory of Molecular Biology,1 Advanced Technology Center, Center for Cancer Research, National Cancer Institute,2 Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland,3 Department of Pathology, Wake Forest University School of Medicine, Winston-Salem, North Carolina4

    3 shared publications
  • Peter McPhie

    National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA

    3 shared publications

Latest Publications

  • Open Access

    Thyroid hormone receptor β mutants: Dominant negative regulators of peroxisome proliferator-activated receptor γ action

    by Osamu Araki, Hao Ying, Fumihiko Furuya, Xuguang Zhu, Sheue-Yann Cheng

    Thyroid hormone (T3) and peroxisome proliferators have overlapping metabolic effects in the maintenance of lipid homeostasis. Their actions are mediated by their respective receptors: thyroid hormone receptors (TR) and peroxisome proliferator-activated receptors (PPAR). We recently found that a dominantly negative TRβ mutant (PV) that causes a genetic disease, resistance to thyroid hormone, acts to repress the ligand (troglitazone)-mediated transcriptional activity of PPARγ in cultured thyroid cells. This finding suggests that TRβ mutants could crosstalk with PPARγ-signaling pathways. The present study explored the molecular mechanisms by which PV represses the PPARγ transcriptional activity. Gel-shift assays show that the PV, similar to wild-type TRβ, bound to the peroxisome proliferator response element (PPRE) as homodimers and heterodimers with PPARγ or the retinoid X receptor (RXR), thereby competing with PPARγ for binding to PPRE and for sequestering RXR. Association of PPRE-bound PV with corepressors [e.g., nuclear receptor corepressor (NCoR)] that led to transcriptional repression was independent of T3 and troglitazone. Chromatin immunoprecipitation assay further demonstrated that, despite the presence of ligands, NCoR was recruited to PPRE-bound PV on a PPARγ-target gene, the lipoprotein lipase, in vivo , suggesting the dominant action of PV on PPARγ-mediated transcriptional activity. Thus, the dominant negative action of PV is not limited on the wild-type TRs. The findings that TRβ mutants affect PPARγ functions through dominant negative action provide insights into the molecular mechanisms by which TR regulates the PPARγ-target genes involved in metabolic pathways, lipid homeostasis, and carcinogenesis.


  • Open Access

    Dual Functions of the Steroid Hormone Receptor Coactivator 3 in Modulating Resistance to Thyroid Hormone

    by Hao Ying, Fumihiko Furuya, Mark C. Willingham, Jianming Xu, Bert W. O'MAlley, Sheue-Yann Cheng

    Mutations of the thyroid hormone receptor β (TRβ) gene cause resistance to thyroid hormone (RTH). RTH is characterized by increased serum thyroid hormone associated with nonsuppressible thyroid-stimulating hormone (TSH) and impaired growth. It is unclear how the actions of TRβ mutants are modulated in vivo to affect the manifestation of RTH. Using a mouse model of RTH that harbors a knockin mutation of the TRβ gene (TRβPV mouse), we investigated the effect of the steroid hormone receptor coactivator 3 (SRC-3) on RTH. In TRβPV mice deficient in SRC-3, dysfunction of the pituitary-thyroid axis and hypercholesterolemia was lessened, but growth impairment of RTH was worsened. The lessened dysfunction of the pituitary-thyroid axis was attributed to a significant decrease in growth of the thyroid and pituitary. Serum insulin-like growth factor 1 (IGF-1) was further reduced in TRβPV mice deficient in SRC-3. This effect led to reduced signaling of the IGF-1/phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway that is known to mediate cell growth and proliferation. Thus, SRC-3 modulates RTH by at least two mechanisms, one via its role as a receptor coregulator and the other via its growth regulatory role through the IGF-1/PI3K/AKT/mTOR signaling.


  • Open Access

    An Unliganded Thyroid Hormone β Receptor Activates the Cyclin D1/Cyclin-Dependent Kinase/Retinoblastoma/E2F Pathway and Induces Pituitary Tumorigenesis

    by Hiroko Furumoto, Hao Ying, G. V. R. Chandramouli, Li Zhao, Robert L. Walker, Paul S. Meltzer, Mark C. Willingham, Sheue-Yann Cheng

    Thyroid-stimulating hormone (TSH)-secreting tumors (TSH-omas) are pituitary tumors that constitutively secrete TSH. The molecular genetics underlying this abnormality are not known. We discovered that a knockin mouse harboring a mutated thyroid hormone receptor (TR) β (PV; TRβPV/PV mouse) spontaneously developed TSH-omas. TRβPV/PV mice lost the negative feedback regulation with highly elevated TSH levels associated with increased thyroid hormone levels (3,3′,5-triiodo-l-thyronine [T3]). Remarkably, we found that mice deficient in all TRs (TRα1−/−TRβ−/−) had similarly increased T3 and TSH levels, but no discernible TSH-omas, indicating that the dysregulation of the pituitary-thyroid axis alone is not sufficient to induce TSH-omas. Comparison of gene expression profiles by cDNA microarrays identified overexpression of cyclin D1 mRNA in TRβPV/PV but not in TRα1−/−TRβ−/− mice. Overexpression of cyclin D1 protein led to activation of the cyclin D1/cyclin-dependent kinase/retinoblastoma protein/E2F pathway only in TRβPV/PV mice. The liganded TRβ repressed cyclin D1 expression via tethering to the cyclin D1 promoter through binding to the cyclic AMP response element-binding protein. That repression effect was lost in mutant PV, thereby resulting in constitutive activation of cyclin D1 in TRβPV/PV mice. The present study revealed a novel molecular mechanism by which an unliganded TRβ mutant acts to contribute to pituitary tumorigenesis in vivo and provided mechanistic insights into the understanding of pathogenesis of TSH-omas in patients.


  • Open Access

    Multi-tissue gene-expression analysis in a mouse model of thyroid hormone resistance

    by Lance D Miller, Peter McPhie, Hideyo Suzuki, Yasuhito Kato, Edison T Liu, Sheue-Yann Cheng

    Resistance to thyroid hormone (RTH) is caused by mutations of the thyroid hormone receptor β (TRβ) gene. To understand the transcriptional program underlying TRβ mutant-induced phenotypic expression of RTH, cDNA microarrays were used to profile the expression of 11,500 genes in a mouse model of human RTH. We analyzed transcript levels in cerebellum, heart and white adipose tissue from a knock-in mouse (TRβPV/PV mouse) that harbors a human mutation (referred to as PV) and faithfully reproduces human RTH. Because TRβPV/PV mice have elevated thyroid hormone (T3), to define T3-responsive genes in the context of normal TRβ, we also analyzed T3 effects in hyperthyroid wild-type gender-matched littermates. Microarray analysis revealed 163 genes responsive to T3 treatment and 187 genes differentially expressed between TRβPV/PV mice and wild-type littermates. Both the magnitude and gene make-up of the transcriptional response varied widely across tissues and conditions. We identified genes modulated in T3-dependent PV-independent, T3- and PV-dependent, and T3-independent PV-dependent pathways that illuminated the biological consequences of PV action in vivo. Most T3-responsive genes that were dysregulated in the heart and white adipose tissue of TRβPV/PV mice were repressed in T3-treated wild-type mice and upregulated in TRβPV/PV mice, suggesting the inappropriate activation of T3-suppressed genes in RTH. Comprehensive multi-tissue gene-expression analysis uncovered complex multiple signaling pathways that mediate the molecular actions of TRβ mutants in vivo. In particular, the T3-independent mutant-dependent genomic response unveiled the contribution of a novel 'change-of-function' of TRβ mutants to the pathogenesis of RTH. Thus, the molecular actions of TRβ mutants are more complex than previously envisioned.


  • Open Access

    Alterations in genomic profiles during tumor progression in a mouse model of follicular thyroid carcinoma

    by Hao Ying, Hideyo Suzuki, Hiroko Furumoto, Robert Walker, Paul Meltzer, Mark C. Willingham, Sheue-Yann Cheng

    The molecular genetics underlying thyroid carcinogenesis is not well understood. We have recently created a mutant mouse by targeting a mutation (PV) into the thyroid hormone receptor β gene (TRβPV mouse). TR β PV/PV mice spontaneously develop follicular thyroid carcinoma through pathological progression of hyperplasia, capsular and vascular invasion, anaplasia and eventually metastasis to distant organs. TR β PV/PV mice provide an unusual opportunity to study the alterations in gene regulation that occur during thyroid carcinogenesis. To this end, we profiled the genomic changes in the thyroids of TR β PV/PV mice at 6 months of age, at which time metastasis had begun. From arrays of 20 000 mouse cDNAs, 185 genes were up-regulated (2–17-fold) and 92 were down-regulated (2–20-fold). Functional clustering of named genes with reported functions (100 genes) indicated that ∼39% of these genes were tumor-, metastasis/invasion- and cell-cycle-related. Among the activated tumor-related genes identified, cyclin D1, pituitary tumor transforming gene-1, cathespin D and transforming growth factor α were also found to over-express in human thyroid cancers. Analyses of the gene profiles suggested that the signaling pathways mediated by thyrotropin, peptide growth factors, transforming growth factor-β, tumor necrosis factor-α and nuclear factor-κB were activated, whereas pathways mediated by peroxisome proliferation activated receptor γ were repressed. These results indicate that complex alterations of multiple signaling pathways contribute to thyroid carcinogenesis. The critical genes associated with thyroid follicular carcinogenesis uncovered in the present study could serve as signature genes for diagnostic purposes, as well as for possible therapeutic targets.


  • A targeted dominant negative mutation of the thyroid hormone α1 receptor causes increased mortality, infertility, and dwarfism in mice

    by Masahiro Kaneshige, Hideyo Suzuki, Kumiko Kaneshige, Jun Cheng, Heather Wimbrow, Carrolee Barlow, Mark C. Willingham, Sheue-Yann Cheng

    Mutations in the thyroid hormone receptor β (TRβ) gene result in resistance to thyroid hormone. However, it is unknown whether mutations in the TRα gene could lead to a similar disease. To address this question, we prepared mutant mice by targeting mutant thyroid hormone receptor kindred PV (PV) mutation to the TRα gene locus by means of homologous recombination (TRα1PV mice). The PV mutation was derived from a patient with severe resistance to thyroid hormone that has a frameshift of the C-terminal 14 aa of TRβ1. We knocked in the same PV mutation to the corresponding TRα gene locus to compare the phenotypes of TRα1 PV/+ mice with those of TRβ PV/+ mice. TRα1 PV/+ mice were viable, indicating that the mutation of the TRα gene is not embryonic lethal. In drastic contrast to the TRβ PV/+ mice, which do not exhibit a growth abnormality, TRα1 PV/+ mice were dwarfs. These dwarfs exhibited increased mortality and reduced fertility. In contrast to TRβ PV/+ mice, which have a hyperactive thyroid, TRα1 PV/+ mice exhibited mild thyroid failure. The in vivo pattern of abnormal regulation of T3 target genes in TRα1 PV/+ mice was unique from those of TRβ PV/+ mice. The distinct phenotypes exhibited by TRα1 PV/+ and TRβ PV/+ mice indicate that the in vivo functions of TR mutants are isoform-dependent. The TRα1 PV/+ mice may be used as a tool to uncover human diseases associated with mutations in the TRα gene and, furthermore, to understand the molecular mechanisms by which TR isoforms exert their biological activities.


  • Open Access

    An Isoform of Branched-chain Aminotransferase Is a Novel Co-repressor for Thyroid Hormone Nuclear Receptors

    by Huei-Min Lin, Masahiro Kaneshige, Li Zhao, Xiaoyong Zhang, John A. Hanover, Sheue-Yann Cheng


  • Silencing of Wnt Signaling and Activation of Multiple Metabolic Pathways in Response to Thyroid Hormone-Stimulated Cell Proliferation

    by L D Miller, K S Park, Q M Guo, N W Alkharouf, R L Malek, N H Lee, E T Liu, S Y Cheng

    Read the full review for this F1000Prime recommended article: Silencing of Wnt signaling and activation of multiple metabolic pathways in response to thyroid hormone-stimulated cell proliferation.